The new week began with a bang at Protagonist Therapeutics (PTGX). In Monday’s session, shares took off to the tune of 94% after the FDA delivered the company some encouraging news. Specifically, the agency lifted the clinical hold on the testing of its experimental blood diseases therapy rusfertide. The biotech is testing rusfertide in patients with rare blood diseases. These include a type of cancer, polycythemia vera, and hereditary hemochromatosis (HH). In September, the FDA had verbally instructed the company to halt all clinical trials after Protagonist informed the regulatory body about mice that had contracted skin cancer following exposure to the treatment.
https://www.tipranks.com/news/article/protagonist-therapeutics-how-much-more-upside-is-left?utm_source=advfn.com&utm_medium=referral
Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Protagonist Therapeutics Charts.
Protagonist Therapeutics (NASDAQ:PTGX)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Protagonist Therapeutics Charts.